Protection against HSV-2 is added benefit of tenofovir

Protection against HSV-2 is added benefit of tenofovir

(HealthDay)—Tenofovir for HIV-1 preexposure prophylaxis (PrEP) provides the added benefit of protection against herpes simplex virus type 2 (HSV-2) acquisition, according to a study published in the July 1 issue of the Annals of Internal Medicine.

Connie Celum, M.D., M.P.H., from the University of Washington in Seattle, and colleagues conducted a study among and women in Kenya and Uganda who were seronegative for HIV-1 and HSV-2, but at high risk for HIV-1 acquisition due to having an infected partner. Participants were randomized to receive daily oral PrEP with antiretroviral tenofovir disoproxil fumarate (TDF) alone or in combination with emtricitabine (FTC-TDF).

The researchers found that 131 participants seroconverted to HSV-2 (79 of 1,041 assigned to tenofovir or FTC-TDF PrEP [HSV-2 incidence, 5.6 per 100 person-years] versus 52 of 481 assigned to [HSV-2 incidence, 7.7 per 100 person-years]). With daily oral PrEP, the hazard ratio (HR) for HSV-2 acquisition was 0.70 (P = 0.047) compared with placebo, with an absolute risk reduction of 2.1 per 100 person-years. The HR for PrEP was 0.67 (P = 0.038) among the 1,044 participants with HSV-2-infected partners, compared to placebo, with an absolute risk reduction of 3.1 per 100 person-years.

"Modest protection against HSV-2 is an added benefit of HIV-1 prevention with oral tenofovir-based PrEP," the authors write.

More information: Full Text (subscription or payment may be required)

Related Stories

Drugs used to treat HIV also reduce risk of HIV infection

date Jul 10, 2012

People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers ...

Recommended for you

HIV reservoirs remain obstacles to cure

date May 19, 2015

Antiretroviral therapy (ART) has proven lifesaving for people infected with HIV; however, the medications are a lifelong necessity for most HIV-infected individuals and present practical, logistical, economic ...

Microclinics help keep Kenyan HIV patients in care

date May 18, 2015

A team led by researchers from UC San Francisco, Organic Health Response, and Microclinic International is reporting results of a study that showed significant benefits of microclinics—an innovative intervention ...

'Redesigned' antibodies may control HIV

date May 18, 2015

With the help of a computer program called "Rosetta," researchers at Vanderbilt University have "redesigned" an antibody that has increased potency and can neutralize more strains of the AIDS-causing human ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.